Commentary: the FDA, politics, and the public

Controlled trials: nuisance or necessity?

Methods of information in medicine·2011

Balancing risks versus benefits in drug therapy decisions.

Clinical therapeutics·1999

Drug safety discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: a regulatory perspective.

Clinical pharmacology and therapeutics·1995

Research and development costs for new drugs by therapeutic category. A study of the US pharmaceutical industry.

PharmacoEconomics·1995

The new drug approvals of 1990, 1991, and 1992: trends in drug development.

Journal of clinical pharmacology·1994

The role of the research-based pharmaceutical industry in medical progress in the United States.

Journal of clinical pharmacology·1993

Arginine Therapy for Sickle Cell Disease Acute Pain Episodes: The STArT Randomized Clinical Trial.

JAMA·2026

Daily Zinc Supplementation for Infection Prevention in Children With Sickle Cell Anemia: The ZIPS-2 Randomized Clinical Trial.

JAMA·2026

When Policy Becomes Personal: Responding with Self-Compassion.

The American journal of nursing·2026

Coping With COVID-19's Demanding Collective Goals: Is a Normative Context in Favour of Governmental Measures Related to Social Cohesion?

Canadian review of sociology = Revue canadienne de sociologie·2026

Message Framing and Regulatory Focus: COVID-19 Vaccination Intentions for Young Children Among Vaccine-Hesitant Parents.

Health communication·2026

Peru's front-of-package warning label policy and changes in the healthfulness of the food supply: a pre-post observational study.

BMJ global health·2026

Impact of 2018 Immigration Policy Shifts on Hispanic HIV Incidence Across Divergent Local Policy Environments in the United States.

The Milbank quarterly·2026

From Vaccine Skepticism to Institutional Distrust: The Post-Pandemic Shift.

Vaccines·2026

Related Experiment Videos

Commentary: the FDA, politics, and the public

Related Concept Videos

Controlled trials: nuisance or necessity?

Balancing risks versus benefits in drug therapy decisions.

Drug safety discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: a regulatory perspective.

Research and development costs for new drugs by therapeutic category. A study of the US pharmaceutical industry.

The new drug approvals of 1990, 1991, and 1992: trends in drug development.

The role of the research-based pharmaceutical industry in medical progress in the United States.

Arginine Therapy for Sickle Cell Disease Acute Pain Episodes: The STArT Randomized Clinical Trial.

Daily Zinc Supplementation for Infection Prevention in Children With Sickle Cell Anemia: The ZIPS-2 Randomized Clinical Trial.

When Policy Becomes Personal: Responding with Self-Compassion.

Coping With COVID-19's Demanding Collective Goals: Is a Normative Context in Favour of Governmental Measures Related to Social Cohesion?

Message Framing and Regulatory Focus: COVID-19 Vaccination Intentions for Young Children Among Vaccine-Hesitant Parents.

Peru's front-of-package warning label policy and changes in the healthfulness of the food supply: a pre-post observational study.

Impact of 2018 Immigration Policy Shifts on Hispanic HIV Incidence Across Divergent Local Policy Environments in the United States.

From Vaccine Skepticism to Institutional Distrust: The Post-Pandemic Shift.

Related Experiment Videos

Commentary: the FDA, politics, and the public

Related Concept Videos

Related Articles